Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Dovato
| Field | Information |
|---|---|
| Medication Name | Dovato |
| Generic Name | Dolutegravir/Lamivudine |
| Boxed/Label Warning | Patients co-infected with HBV: Severe acute exacerbations of hepatitis B can occur upon discontinuation of Dovato. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HBV and discontinue Dovato. |
| Purpose | Complete regimen for the treatment of HIV-1 infection in adults. |
| Mechanism of Action | Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI) which inhibits both HIV-1 and HIV-2 reverse transcriptase. |
| Dosage Forms | Oral tablets |
| Available Strengths | 50 mg dolutegravir / 300 mg lamivudine |
| Dosage Frequency | Once daily |
| Common Side Effects | Headache, diarrhea, nausea, insomnia, fatigue |
| Serious Side Effects | Severe allergic reactions, liver problems, depression or mood changes, lactic acidosis |
| Drug Interactions | Metformin, rifampin, certain antacids (containing aluminum or magnesium), some anticonvulsants (e.g., carbamazepine, phenytoin), St. John’s Wort |
| Important Notes | Dovato is a complete HIV-1 treatment regimen. Do not take with other HIV medications unless directed by your doctor. Consult your healthcare provider if you experience any new or worsening symptoms. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | Take as soon as you remember; skip if it’s almost time for your next dose. Do not double the dose. |
| Alternatives | Triumeq (dolutegravir/abacavir/lamivudine), Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Descovy (emtricitabine/tenofovir alafenamide) + Tivicay (dolutegravir) |
Dovato Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Triumeq (dolutegravir/abacavir/lamivudine) | Integrase inhibitor and NRTIs | Complete regimen, requires HLA-B*5701 testing for abacavir. |
| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) | Integrase inhibitor and NRTIs | Complete regimen, generally well-tolerated. |
| Descovy (emtricitabine/tenofovir alafenamide) + Tivicay (dolutegravir) | NRTIs and Integrase Inhibitor | Two-pill regimen providing similar drug components. |
Dovato Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Headache | Severe allergic reactions (rash, swelling, difficulty breathing) |
| Diarrhea | Liver problems (yellowing of skin or eyes, dark urine) |
| Nausea | Depression or mood changes |
| Insomnia | Lactic acidosis (muscle pain, weakness, trouble breathing) |
| Fatigue | New or worsening kidney problems |
Dovato Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| HIV-1 Infection | One tablet daily | One tablet daily | May be taken with or without food. Do not take with other dolutegravir or lamivudine containing products. |
Dovato Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $5 – $50 |
| Without Insurance (U.S.) | $3,000 – $3,500 |
| From CPS | $1,249.95 |
